Send feedback

BRCA2 p.Trp2619Cys

c.7857G>C · rs80359011 · VCV438744

Likely pathogenic Expert panel
Classification
Likely pathogenic
ClinVar
Review
Expert panel ★★★☆
ClinVar · 8 submitters
AlphaMissense
likely pathogenic
0.9802 · ACMG-weighted
gnomAD v4.1
Absent
absent from gnomAD v4.1
Missense predictors
2/2 damaging
AlphaMissense, REVEL
Conditions
4
BRCA2-related cancer predisposition

ClinGen expert panel — ENIGMA BRCA1 and BRCA2 VCEP

Likely Pathogenic for BRCA2-related cancer predisposition. Applied ACMG criteria (verbatim):

PM2_Supporting PS3 PP3

Curation rationale (ClinGen, verbatim)

The variant c.7857G>C in BRCA2 is a missense variant predicted to cause substitution of Tryptophan by Cysteine at amino acid 2619 (p.Trp2619Cys). This variant is absent from gnomAD v2.1 (exomes only, non-cancer subset, read depth ≥25) and gnomAD v3.1 (non-cancer subset, read depth ≥25) (PM2_Supporting met). This BRCA2 missense variant is within a key functional domain and the computational predictor BayesDel (noAF) gives a score of 0.49, above the recommended threshold of 0.30 for prediction of impact on BRCA2 function via protein change. A SpliceAI score of 0.17 indicates an unclear predicted impact on splicing (score threshold 0.10-0.20) (PP3 met). Reported by four calibrated studies to exhibit protein function similar to pathogenic control variants (PMIDs: 38417439, 32444794, 39779857, 39779848) (PS3 met). Multifactorial likelihood ratio analysis using clinically calibrated data produced a combined LR for this variant of 1.81 (based on Family History LR=1.81), which is above the ENIGMA BRCA1/2 VCEP threshold for BP5 (>0.48) and below PP4 (<2.08) (BP5 and PP4 not met; PMIDs 31853058). In summary, this variant meets the criteria to be classified as a likely pathogenic variant for BRCA2-related cancer predisposition based on the ACMG/AMP criteria applied as specified by the ENIGMA BRCA1/2 VCEP (PS3, PM2_Supporting, PP3).

ClinGen Evidence Repository → · reported verbatim, not re-tallied by Sugi Variant.

Computational evidence

Protein change
AlphaMissense0.9802likely pathogenic ✓ concordant with ClinVar · top 1% in BRCA2
REVEL0.904moderately pathogenic-leaning
⇒ AlphaMissense and REVEL both call this damaging.
Splicing
SpliceAI<0.2all four deltas below 0.2 · G>T here scores Δ0.55 · evaluated, not missing
Constraint at this position
ConservationphyloP 12GERP 2.5, phastCons 1
Regional constrainto/e 1.03unconstrained · MANE · 47 kb · p 0.059 · regional, not allelic
Overall
CADD32.0PHRED · no single calibrated threshold — expert panels disagree

AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.

Population frequency

gnomAD v4.1 · exomes + genomes

Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.

Variant & gene context

Gene
BRCA2
Protein
p.Trp2619Cys
Coding
c.7857G>C
MANE Select
NM_000059
dbSNP
rs80359011
Type
single nucleotide variant
Location
chr13:32362574 (GRCh38)
Gene constraint
LOEUF 0.803 · pLI <0.01 · ClinGen HI 3/3 (gnomAD)
Residue 2619
the 'interaction with sem1' region
Full BRCA2 gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Similar variants

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/brca2-p-trp2619cys (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown